TY  - RPRT
TI  - Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.
AU  - Michel Vulfovich
AU  - Nabil Saba
PY  - 2005
UR  - https://pubmed.ncbi.nlm.nih.gov/16248286/
ID  - 16248286
ER  -